The combination of Peptide YY 3 – 36 with GLP-17 – 36 amide causes an increase in first-phase insulin secretion in response to IV glucose

Context: The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY3–36 and GLP-17–36 amide,on glucose homeostasis are unknown. Objective: To investigate the acute effects of PYY3–36 and GLP-17–36 amide, individually and in combination, on insulin secretion and sensitivity.